# Zepp Health Corp: Form 20-F for the period ended Dec 31, 2019

- Company: [Zepp Health Corp](/companies/zepp.md) (CIK 1720446)
- Form: 20-F
- Filed: 2020-04-23
- Accepted by EDGAR: Apr 23, 2020, 16:12 ET
- Period: 2019-12-31
- Accession: 0001104659-20-050322
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1720446/000110465920050322/a20-3630_120f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1720446/000110465920050322/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2019-01-01 to 2019-12-31 | $834.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2019-01-01 to 2019-12-31 | $624.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2019-01-01 to 2019-12-31 | $210.8m | us-gaap:GrossProfit |
| Research and development | 12 months, 2019-01-01 to 2019-12-31 | $61.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2019-01-01 to 2019-12-31 | $87.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2019-01-01 to 2019-12-31 | $11.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2019-01-01 to 2019-12-31 | $82.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2019-01-01 to 2019-12-31 | $0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2019-01-01 to 2019-12-31 | $0.34 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2019-01-01 to 2019-12-31 | 255,959,172 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2019-01-01 to 2019-12-31 | $61.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2019-01-01 to 2019-12-31 | $4.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2019-01-01 to 2019-12-31 | $652.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2019-12-31 | $259.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-12-31 | $630.9m | us-gaap:AssetsCurrent |
| Total assets | at 2019-12-31 | $743.3m | us-gaap:Assets |
| Current liabilities | at 2019-12-31 | $356.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-12-31 | $384.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-12-31 | $359.2m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1720446/000110465920050322/a20-3630_120f.htm

Filed Apr 23, 2020.
Source: SEC EDGAR, the filing index for accession 0001104659-20-050322. Last ingested by Listed: Nov 5, 2026, 14:06 ET. No prices; not investment advice.